Login to Your Account



Pharma: Other News To Note


Thursday, February 16, 2012
• Pfizer Inc., of New York, said the FDA accepted for review the new drug application for tafamidis meglumine, its oral treatment for transthyretin familial amyloid polyneuropathy, a rare, progressive and fatal neurodegenerative disease that affects about 8,000 patients worldwide. Tafimidis, which Pfizer gained through its 2010 acquisition of privately held FoldRx Pharmaceuticals Inc., of Cambridge, Mass., was granted a priority review and has a PDUFA date in June 2012. Last year, the drug was approved in Europe, where it's sold under the brand name Vyndaqel.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription